Indeed, relapsing patients with FLT3 negative AML at diagnosis can acquire this mutation, eventually along with other abnormalities, such as TP53, KIT, RUNX1, and WT1, at relapse [39,46,47,49]. This evidence concerns the gene TP53 and acute myeloid leukemia.